 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | IQVIA Consulting and Information services India private limited |
| Street 1: | Dr. Gopaldas Bhawan, 28 Barakhamba Road |
| Street 2: | |
| City: | New Delhi |
| Province: | |
| Post Code: | 110001 |
| Country: | India |
| Phone: | +91114975800 |
| Organization Email: | lokesh.sharma@in.imshealth.com |
| Web Site: | http://www.iqvia.com/ |
| Other Online Presence: | |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | Private sector |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | Company |
| Organization Description: | |
| IQVIA’s mission Healthcare is an industry designed to help humans. As a global community, we continuously invest and commit to advancing human health. To deliver value and real outcomes. To rise to the challenge to find the next breakthrough by making the most of increasingly limited resources. We are inspired by the potential and propelled by the possibilities. We share the vision to drive healthcare forward. To see how we can help accelerate progress and achievements. Others are developing these medical breakthroughs. We do our part by using breakthroughs in insights, technology and human intelligence to reimagine and deliver ways to help make them a reality. Focus work IQVIA consulting and information services India private limited is the world’s leading provider of healthcare consulting, research & data analytics services with over 60 years of experience. We operate in over 100 countries and serve over 5,000 healthcare customers across 6 continents. IQVIA serves key healthcare organizations and decision makers around the world, spanning government agencies, donor agencies, policymakers, researchers and the breadth of life science and healthcare companies, consumer health and medical device manufacturers, as well as distributors, providers, payers, and the financial community. The focus areas of work are:- Unparalleled data and analytics • IQVIA is the world leader having repository of complex data and generating analytics thereof. The data is scalable, intent to provide richer insights and evidences and enable new ways to engage payers and providers to ensure patients benefit from the particular treatment or from the particular intervention Research and Development • IQVIA provides the expertise and innovative approaches to get the product through the complexities of clinical development and to market it faster with a stronger value story Innovation and Technologies • Our technology investments helps to bring the patients a faster treatment option, ensure regulatory compliance, and incr |
|
| Do you know about the UNHLM declaration: | |
Specializations / Areas of Work | |
|
Advocacy Civil Society and Community Engagement Funding, including innovative and optimized approach to funding TB Care Research and Development Technical Assistance |
Other Organization Information | |
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 11 - 25 |
| Number of part-time staff who are directly involved with TB: | 100 + |
| Number of volunteers who are directly involved with TB: | 0 |
| How did you hear about the Stop TB Partnership: | Involvement in TB control provision |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Technical assistance and advice |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| IQVIA has rich technical expertise in the field of TB owing to its deep engagement with various organizations in the space of TB prevention and treatment. IQVIA is the only consulting firm in India which has supported BMGF’s India TB program for promoting private sector engagement over the past 2 years. IQVIA’s role spans segmentation, prioritization and profiling of providers and chemists and setting up of surveillance system to track TB treatment practices. Further, IQVIA has in-house proprietary healthcare informatics database of anti TB drug sales in India, TB prescriptions and drug manufacturers etc. The findings of patient month’s estimation and private sector landscape assessment laid the foundation of including the private sector into national strategic plan for TB control 2017-25.The NSP 2017-25 has defined various stages and strategies for achieving the desired goals, out of which IQVIA through its various programs contribute towards to achieve the below mentioned: Case finding • Through the initiative of conducting the active case finding efforts with 175000 mining population of Maharashtra, IQVIA aims to develop a roadmap and contribute into the case finding efforts as defined into NSP 2017-25 Patients in private sector • Inclusion of private providers into the real time case finding, managing and treating scenario has been a focus reflected into the projects and strategies conducted by IQVIA. The private sector landscape assessment, prescription analysis, PPIA model of TB treatment, adherence to medication by patients taking treatment through private providers has produces evidences for need of bringing the private providers in the forefront for TB treatment and management Treatment services • The flagship project of utilizing technology for improving the adherence to the TB medication has proved to be efficient for improving the treatment services to the patients. Currently deployed with 722 patients across India, with 75% being adherent to medication is a sure evidence of role of technology into delivery of treatment services. Capacity building of the healthcare providers on program roll out as well as on TB related instruction is an inevitable part of the whole deployment process. IQVIA also ensures streamline of supply and procurement structure of the particular deployment site through laisioning with state and district level health authorities Key affected population • With its pan India coverage, the projects have focused on including all the key affected population such as mining workers and their family, population residing in hard to reach areas with limited access to health services, population living in slums and over-populated spaces, old age population, pediatric population, population with poor health seeking behavior and socio-economic conditions |
|
Geographical Reach | |
| Which country is your headquarters located in: | United States of America |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Bangladesh Cambodia Cameroon Canada China Cote d'Ivoire Ghana India Indonesia Jordan Kenya Lao People's Democratic Republic Lebanon Nepal Nigeria Pakistan Qatar Saudi Arabia Singapore South Africa South Sudan Sri Lanka Sudan Thailand Turkey Uganda United Arab Emirates United Kingdom of Great Britain and Northern Ireland United States of America Viet Nam |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
TB Care Delivery: The global plan to stop TB 2016-2020 have very strategically defined and curated the theme of “The paradigm shift” which by its name shout outs the uniqueness in the approach and efforts required to achieve the mentioned target and to realize a world free of tuberculosis-zero deaths, disease and suffering due to tuberculosis as a part of overall vision. As a part of the 90-90-90 strategy, various countries have been grouped together and investment strategy packages have been curated to accelerate their efforts towards achieving the targets. Owing to India’s TB burden and healthcare scenario, the global plan has accounted India as a separate setting and has suggested a package of most effective and appropriate Interventions to endeavor India’s efforts towards TB elimination. IQVIA being a leading healthcare research and management consulting firm with its operation across the globe, has established its name in TB related data collection, analysis, policy advocacy and use of technology in TB treatment and management domain in India. The experience and work done by IQVIA resonates with the interventions mentioned in the investment package for India as given in the Global plan. The proposed intervention such as taking advantage of modern technology for improving public-sector-funded program, reforming and modernizing TB care in public sector, improving the quality of care in private sector, scaling up special models of care for the poor residing in large cities, establishing electronic web-based, mobile based, and call-center-based models for notification, and incorporating information technology in key program functions have been addressed by various projects and programs done by IQVIA. • Program management, monitoring & evaluation for TB PPIA (Private Provider Interface Agency) project across various cities in India. Year of start- 2014 Country-India The program aimed at promoting private sector engagement through Private Public Interface Agency (PPIA). The PPIAs acts to bridge the gap for quality services by ensuring conclusive and reliable tests, early case detection, appropriate treatment regimen and value for money for the TB patients that opt for private sector as a first point of treatment initiation. The main focus of the program has been the private healthcare provider landscape assessment and utilizing the drug sales data to estimate the patient month into treatment, • Project implementation, management to deploy and evaluate 99DOTS and the Medication Event Reminder Monitor device ""MERM") as "Pill in Hand" TB adherence monitoring solutions Year of start- 2016 Country-India Adherence to TB treatment is one of the biggest barrier to positive treatment outcomes across the world. Through “Pill in Hand” technologies such as 99DOTS and MERM (Medicine Event Reminder Monitor) devices exemplifies the perfect blend of technology and health sciences and has proved its efficiency in improving the adherence for TB treatment as well as reducing the overall cost of program. I IQVIA is the only firm in India which is supporting in designing, implementing and evaluating these two technologies among TB patients. Till now, MERM has been rolled out with more than 722 patients across India covering the varied geographies, hard to reach population, socio-economic backgrounds, slum dwellers, TB case scenarios (DSTB and DRTB), public and private sectors and adult and pediatric TB population. Due to ease in using these technologies, the adherence to TB treatment has been ensured among migrant population and daily wage laborers by eliminating the factor of daily visiting the health provider. The once in week or monthly visit aids into saving the time and cost both for provider and beneficiaries while ensuring better program activities management. As the daily adherence get recorded on the digital dashboard, this serves as an evidence to estimate the TB burden across nation. Drug-Resistant TB: Drug-resistant TB can occur when the drugs used to treat TB are misused or mismanaged. Examples of misuse or mismanagement include people do not complete a full course of TB treatment, health care providers prescribe the wrong treatment (the wrong dose or length of time), drugs for proper treatment are not available, drugs are of poor quality. Drug-resistant TB is more common in people who do not take their TB drugs regularly, do not take all of their TB drugs and develop TB disease again after being treated for TB disease in the past, come from areas of the world where drug-resistant TB is common, have spent time with someone known to have drug-resistant TB disease. As a part of the TB program portfolio and though the project taken up by IQVIA, the focus has been on preventing the conversion of DSTB into DRTB as well to reduce the current burden of DRTB by ensuring the adherence to the TB medications. The public and private healthcare providers engaged with the program are also capacitated with the latest norms and treatment guidelines to ensure the universally prescribed quality TB treatment guidelines. The comprehensive database stating the treatment adherence status and treatment completion outcome which can be leveraged for tracking the registered patients and the gaps in the prescribed treatment regimens. Research: Leveraging on its proprietary pharma data, IQVIA provided technical assistance for computing “TB patient-months” for estimating the real TB load in private sector in India, This formed an baseline indicator for quality assurance to measure the program coverage of notified cases in the private sector against the estimated number of patients being treated in private sector using drug sales data and has been published in the Lancet Journal of Infectious disease in 2016 The midpoint of the study yields an estimate of 2·2 million cases, two to three times higher than assumed. Through the study it was estimated that India’s private sector is treating an enormous number of patients for tuberculosis, appreciably higher than has been previously recognized. Accordingly, there is a re-doubled need to address this burden and to strengthen surveillance. Tuberculosis burden estimates in India and worldwide require revision. The landscape assessment among private sector and outcome evaluation studies done through capturing the impact of medication adherence to the TB cure rate have provided huge insights into country’s TB scenario. |
|
Declaration | |
| Declaration of interests: As a private sector consulting and information services organization, we do work with pharmaceutical companies, providers and other healthcare stakeholders on a commercial basis as these are our clients. Many of them do have a TB portfolio of drugs, medical devices etc. However, we do not see any direct or indirect conflict of interest as firstly different teams work with private sector and information confidentiality is maintained | |
| Application date: | July 2, 2018 |
| Last updated: | July 11, 2018 |